Top 20 Global Chemical Companies by Revenue in 2025

Resonac Holdings announced its 2025 financial results. Full-year revenue totaled ¥1.3471 trillion (approximately USD 8.458 billion), down from ¥1.3915 trillion in the prior year. Full-year operating profit amounted to ¥46.7 billion, compared to ¥89.0 billion in the prior year. Net income attributable to owners of parent stood at ¥29.0 billion, down from ¥73.5 billion in the prior year. Yuntianhua released its 2025 annual report. The company’s full-year revenue was RMB 48.41 billion (approximately USD 7.09 billion), a 21.3% decline year-on-year; net income attributable to shareholders was RMB 5.16 billion, down 3.3% year-on-year. In Q4 alone, revenue was RMB 10.82 billion, down 27.0% year-on-year; net income attributable to shareholders was RMB 427 million, down 53.0% year-on-year. United States Dow Inc. reported its Q4 and full-year 2025 results. Q4 net sales were USD 9.46 billion, down from USD 10.405 billion in the prior-year quarter. Net loss attributable to common shareholders for the quarter was USD 1.543 billion, versus a net loss of USD 53 million in the prior-year quarter. Full-year net sales totaled USD 39.968 billion, down from USD 42.964 billion in 2024. Full-year net loss attributable to common shareholders was USD 2.623 billion, versus net income of USD 1.116 billion in 2024. Ecolab Inc. reported its Q4 and full-year 2025 results. Q4 net sales were USD 4.196 billion, up 5% year-on-year from USD 4.005 billion. Operating profit for the quarter was USD 712 million, up 22% year-on-year from USD 583 million. Net income attributable to the company was USD 564 million, up 19% year-on-year from USD 473 million. Full-year net sales totaled USD 16.081 billion, up 2% year-on-year from USD 15.741 billion. Full-year operating profit was USD 2.738 billion, down 2% year-on-year from USD 2.802 billion. Full-year net income attributable to the company was USD 2.076 billion, down 2% year-on-year from USD 2.112 billion. Westlake Corporation reported its Q4 and full-year 2025 results. Q4 net sales were USD 2.533 billion, down from USD 2.843 billion in the prior-year quarter. Net loss attributable to the company for the quarter was USD 544 million, versus a net loss of USD 782 million in the prior-year quarter. Full-year net sales totaled USD 11.17 billion, down from USD 12.142 billion in 2024. Full-year net loss attributable to the company was USD 1.508 billion, versus net income of USD 602 million in 2024. International Flavors & Fragrances Inc. (IFF) reported its Q4 and full-year 2025 results. Q4 net sales were USD 2.589 billion, down 7% year-on-year from USD 2.771 billion. Operating profit for the quarter was USD 97 million, down 24% year-on-year from USD 127 million. Net income attributable to shareholders was USD 18 million, versus a net loss of USD 60 million in the prior-year quarter. Full-year net sales totaled USD 10.89 billion, down 5% year-on-year from USD 11.184 billion. Full-year operating loss was USD 382 million, versus operating income of USD 766 million in 2024.

2026 Pharmaceutical Industry Outlook: Ecolab Executive Reveals Three Make-or-Break Battles for Cost Reduction and Efficiency Gains—AI and Continuous Manufacturing as Decisive Factors

1. AI: From ‘Supporting Tool’ to ‘Core Decision-Maker’ ・R&D: AI has compressed the new molecule design cycle from ‘months’ to ‘weeks’, fundamentally shifting the starting line for novel drug discovery. ・Manufacturing: Predictive maintenance is eliminating batch failures; real-time quality analytics are enabling lightning-fast release decisions. AI eradicates ‘uncertainty’ in production—clearing the biggest obstacle to continuous manufacturing. Mello stated bluntly: “Digital technologies have shifted from ‘nice-to-have’ to an all-out race where hesitation means falling behind. In 2025, companies that hesitated were forced into full-speed catch-up.” 2. Continuous Manufacturing: A Dual ‘Paradigm Shift’ in Efficiency and Quality This is not merely about being ‘faster’—it represents a complete reconstruction of production logic. ・Data evidence: Real-world cases show continuous manufacturing can shorten production cycles by 30–40%, while simultaneously improving product consistency. ・Fundamental transformation: It redefines the core principles of quality control and process scale-up, unlocking optimization opportunities inaccessible under traditional batch production. 3. Sustainability: From ‘Cost Center’ to ‘Profit Center’ A pivotal shift in 2025 is that energy and water conservation are no longer pursued solely for regulatory compliance or corporate image. ・New mindset: Reducing water and energy consumption directly boosts profitability and strengthens operational resilience. ・New positioning: Sustainability has become a tangible competitive advantage—and a genuine business moat. III. Three Inescapable Challenges Even though the technology is promising, comprehensive implementation still faces tough hurdles: 1. Regulatory ‘Black Box’: How does AI make critical decisions? Regulators demand absolute transparency and explainability. 2. Legacy Gap: How do we enable state-of-the-art AI systems to interface with aging equipment and legacy systems—many over 10–15 years old? 3. Security Baseline: Data sovereignty and cybersecurity are non-negotiable lifelines—not vulnerabilities to be patched after the fact. IV. Supply Chain Relationship Transformation: From ‘Client–Vendor’ to ‘Shared Destiny Partner’ Relationships between pharmaceutical companies and their suppliers are undergoing a fundamental shift: ・Old model: Simple buying-and-selling, transactional supply. ・New model: Strategic co-development, shared technology, and shared risk—true symbiosis. ・New objective: Through tight collaboration—or even M&A—rapid integration of cutting-edge technologies is essential to keep pace with rapidly evolving markets. Mello observed: “They no longer need vendors—they need strategic partners capable of co-innovating and solving the most complex process challenges.”